Clinical Trials
526
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (475 trials with phase data)β’ Click on a phase to view related trials
Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs
- Conditions
- Skin Cancer
- First Posted Date
- 2025-10-31
- Last Posted Date
- 2025-11-03
- Target Recruit Count
- 2900
- Registration Number
- NCT07222995
- Locations
- πΊπΈ
Moffitt Cancer Center, Tampa, Florida, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
ProSalud in Latinos Living in Rural/Agricultural Communities Within Moffitt's Catchment Area
- Conditions
- Cancer
- First Posted Date
- 2025-10-20
- Last Posted Date
- 2025-10-20
- Target Recruit Count
- 50
- Registration Number
- NCT07218848
- Locations
- πΊπΈ
Moffitt Cancer Center, Tampa, Florida, United States
πΊπΈUniversity of South Florida, Tampa, Florida, United States
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
- Conditions
- Metastatic Ewing Sarcoma
- Interventions
- First Posted Date
- 2025-09-26
- Last Posted Date
- 2025-10-20
- Target Recruit Count
- 15
- Registration Number
- NCT07194044
- Locations
- πΊπΈ
University of Alabama at Birmingham (Children's of Alabama), Birmingham, Alabama, United States
πΊπΈPhoenix Children's Hospital, Phoenix, Arizona, United States
πΊπΈConnecticut Children's Medical Center, Hartford, Connecticut, United States
Compare Airway Pressure Release Ventilation (APRV) to Conventional Mechanical Ventila
- Conditions
- Gynecologic CancerGenitourinary Cancer
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-09-10
- Target Recruit Count
- 12
- Registration Number
- NCT07111039
- Locations
- πΊπΈ
Moffitt Cancer Center, Tampa, Florida, United States
Breast Cancer Survivors RESET (Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools): A Pilot, Feasibility Study
- Conditions
- Breast CancerObesity
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-03
- Target Recruit Count
- 37
- Registration Number
- NCT07101861
- Locations
- πΊπΈ
Moffitt Cancer Center, Tampa, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 106
- Next
News
ASCO 2025 Showcases Advances in Myelofibrosis Treatment with Novel JAK Inhibitors and Personalized Approaches
The 2025 ASCO Annual Meeting highlighted significant progress in myelofibrosis treatment, featuring novel JAK inhibitors like momelotinib and pacritinib that offer alternatives to standard ruxolitinib therapy.